
Evofem Biosciences Inc (NASDAQ:EVFM) shares are trading lower by 59.76% at $0.44 after the company announced the pricing of a roughly $26.6 million public offering.
Evofem says the company intends to use the net proceeds from the offering for the continuation of commercialization activities related to its commercial product, Phexxi®. The offering is expected to close on or about May 24, 2022, subject to satisfaction of customary closing conditions.